Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a studyVolkan Granit, Matthew T. Duvernay, Michael Benatar et al.|The Lancet Neurology|2023Cited by 255
Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysisScott Goldsmith, Marcie Riches, Miguel Ángel Díaz et al.|Blood|2021Cited by 177
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)Ankit Kansagra, Shahrukh K. Hashmi, Noelle V. Frey et al.|Bone Marrow Transplantation|2019Cited by 119
Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular TherapyAnkit Kansagra, Shahrukh K. Hashmi, Noelle V. Frey et al.|Biology of Blood and Marrow Transplantation|2018Cited by 106
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphomaJoanna Zurko, Alex F. Herrera, Jeremy Ramdial et al.|Haematologica|2022Cited by 73